Table.1.
Baseline characteristics of the patients by 5% weight change from baseline
| Characteristic | Weight loss ≥ 5% | Stable weight | Weight gain ≥ 5% | P-value |
|---|---|---|---|---|
| N | 1044 | 2677 | 1659 | |
| Age, years | 61.3 ± 10.0 | 61.7 ± 10.0 | 59.3 ± 9.6 | < 0.001 |
| Age > 65 year | 391 (37.5%) | 1052 (39.3%) | 464 (28.0%) | < 0.001 |
| Female, n (%) | 397 (38.0%) | 843 (31.5%) | 489 (29.5%) | < 0.001 |
| Diabetes duration, years | 7.5 (2.8, 14.0) | 7.1 (2.9, 13.3) | 6.9 (2.4, 14.0) | 0.43 |
| Glycated hemoglobin, % | 8.0 ± 1.1 | 8.0 ± 1.1 | 8.1 ± 1.1 | 0.030 |
| Insulin, n (%) | 300 (28.7%) | 782 (29.2%) | 523 (31.5%) | 0.19 |
| Metformin, n (%) | 701 (67.1%) | 1776 (66.3%) | 1085 (65.4%) | 0.63 |
| Sulfonylureas, n (%) | 445 (42.6%) | 1270 (47.4%) | 788 (47.5%) | 0.019 |
| Thiazolidinediones, n (%) | 38 (3.6%) | 49 (1.8%) | 44 (2.7%) | 0.004 |
| Weight at baseline, Kg | 84.5 ± 21.0 | 83.6 ± 18.6 | 78.5 ± 18.3 | < 0.001 |
| BMI at baseline, Kg/m2 | 30.5 ± 6.3 | 29.7 ± 5.4 | 28.4 ± 5.3 | < 0.001 |
| Race | < 0.001 | |||
| White | 735 (70.4%) | 2051 (76.6%) | 1123 (67.7%) | |
| Asian | 232 (22.2%) | 479 (17.9%) | 378 (22.8%) | |
| Black | 57 (5.5%) | 79 (3.0%) | 80 (4.8%) | |
| Other | 20 (1.9%) | 68 (2.5%) | 78 (4.7%) | |
| Current smoker, n (%) | 145 (13.9%) | 374 (14.0%) | 215 (13.0%) | 0.62 |
| Hypertension, n (%) | 889 (85.2%) | 2279 (85.1%) | 1301 (78.4%) | < 0.001 |
| HF history, n (%) | 298 (28.5%) | 836 (31.2%) | 399 (24.1%) | < 0.001 |
| Prior stroke, n (%) | 85 (8.1%) | 190 (7.1%) | 113 (6.8%) | 0.40 |
| PAD, n (%) | 122 (11.7%) | 266 (9.9%) | 126 (7.6%) | 0.001 |
| Atrial fibrillation, n (%) | 95 (9.1%) | 190 (7.1%) | 91 (5.5%) | 0.002 |
| MI (index event), n (%) | 794 (76.3%) | 1993 (74.7%) | 1365 (82.3%) | < 0.001 |
| Unstable angina (index event), n (%) | 246 (23.7%) | 675 (25.3%) | 293 (17.7%) | |
| Hemoglobin, g/dl | 13.2 ± 1.6 | 13.6 ± 1.6 | 13.4 ± 1.5 | < 0.001 |
| Anemia, n (%) | 312 (30.0%) | 623 (23.3%) | 433 (26.1%) | < 0.001 |
| eGFR, ml/min/1.73m2 | 67.5 ± 21.2 | 71.1 ± 21.1 | 72.8 ± 21.8 | < 0.001 |
| eGFR < 60 ml/min, n (%) | 353 (33.8%) | 761 (28.4%) | 451 (27.2%) | < 0.001 |
| Heart rate, bpm | 72.1 ± 11.2 | 70.8 ± 10.7 | 71.8 ± 10.7 | < 0.001 |
| SBP, mmHg | 129.7 ± 17.4 | 129.9 ± 15.8 | 127.1 ± 17.3 | < 0.001 |
| SBP > 140/90 mmHg, n (%) | 238 (22.8%) | 545 (20.4%) | 297 (17.9%) | 0.007 |
| Total cholesterol, mg/dl | 146 (123, 148) | 149 (126, 178) | 143 (122, 173) | 0.001 |
| HDL cholesterol, mg/dl | 42 (36, 48) | 42 (36, 49) | 42 (35, 48) | 0.11 |
| LDL cholesterol, mg/dl | 72 (55, 97) | 74 (55, 97) | 70 (53, 94) | 0.010 |
| Triglycerides, mg/dl | 138 (102, 192) | 143 (104, 200) | 139 (102, 191) | 0.12 |
| Antiplatelets at baseline, n (%) | 1008 (96.6%) | 2600 (97.1%) | 1624 (97.9%) | 0.10 |
| Beta-blockers at baseline, n (%) | 836 (80.1%) | 2220 (82.9%) | 1355 (81.7%) | 0.12 |
| Statins at baseline, n (%) | 930 (89.1%) | 2402 (89.7%) | 1534 (92.5%) | 0.003 |
| CCBs at baseline, n (%) | 244 (23.4%) | 641 (23.9%) | 312 (18.8%) | < 0.001 |
| Diuretics at baseline, n (%) | 432 (41.4%) | 988 (36.9%) | 594 (35.8%) | 0.010 |
| ACEi or ARB at baseline, n (%) | 856 (82.0%) | 2227 (83.2%) | 1328 (80.0%) | 0.033 |
| Randomization to alogliptin | 541 (51.8%) | 1332 (49.8%) | 828 (49.9%) | 0.51 |
BMI, body mass index; PAD, peripheral artery disease; MI, myocardial infarction; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; CCBs, calcium channel blockers; ACEi/ARBs, angiotensin converting enzyme inhibitors/angiotensin receptor blockers